Lack of a pharmacokinetic drug-drug interaction with venlafaxine extended-release/indinavir and desvenlafaxine extended-release/indinavir

Michael W. Jann, Vicky Spratlin, Kathryn Momary, Hailing Zhang, David Turner, Scott R. Penzak, Alan Wright, Chad VanDenBerg

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Purpose: To assess the effects of venlafaxine extended-release (XR) capsules and desvenlafaxine extended-release (XR) tablets upon indinavir pharmacokinetic properties when co-administrated to healthy volunteers. Methods: This was an open-label, two-period, fixed-dose study conducted at the clinical research unit located on a university campus. Twenty-four healthy volunteers enrolled in the study (mean age 28.3±8.0 years). Each subject received a single dose of indinavir 800 mg on day 1. Subsequently, subjects were then randomly assigned to either the venlafaxine XR group (N012) or the desvenlafaxine XR group (N012). Starting on day 2, venlafaxine XR was dosed at 37.5 mg/day for 4 days and increased to 75 mg/day for 6 days. Desvenlafaxine XR was dosed at 50 mg/day for 10 days. On day 12, indivanvir 800 mg was co-administered to both the venlafaxine XR and the desvenlafaxine XR groups. The pharmacokinetics of indinavir were determined both before and at the end of antidepressant dosing. Plasma indinavir, venlafaxine, and desvenlafaxine concentrations were assayed by highperformance liquid chromatography with ultra-violet (UV) detection. Indinavir pharmacokinetic parameters were calculated by noncompartmental analysis using validated computer software. Results: Venlafaxine XR and desvenlafaxine XR did not produce any significant changes in indinavir disposition. Both antidepressants were well tolerated by the subjects with only minor adverse side effects. Conclusions: No pharmacokinetic drug-drug interaction was demonstrated between venlafaxine XR and indinavir or between desvenlafaxine XR and indinvair. The lack of interaction could be due to the venlafaxine and desvenlafaxine extended-release formulation.

Original languageEnglish (US)
Pages (from-to)715-721
Number of pages7
JournalEuropean Journal of Clinical Pharmacology
Volume68
Issue number5
DOIs
StatePublished - May 1 2012

Fingerprint

Indinavir
Drug Interactions
Pharmacokinetics
Pharmaceutical Preparations
Antidepressive Agents
Healthy Volunteers
Desvenlafaxine Succinate
Venlafaxine Hydrochloride
Liquid Chromatography
Tablets
Capsules
Software

Keywords

  • Desvenlafaxine XR
  • Drug interaction
  • Indinavir
  • P-glycoprotein
  • Venlafaxine XR

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Lack of a pharmacokinetic drug-drug interaction with venlafaxine extended-release/indinavir and desvenlafaxine extended-release/indinavir. / Jann, Michael W.; Spratlin, Vicky; Momary, Kathryn; Zhang, Hailing; Turner, David; Penzak, Scott R.; Wright, Alan; VanDenBerg, Chad.

In: European Journal of Clinical Pharmacology, Vol. 68, No. 5, 01.05.2012, p. 715-721.

Research output: Contribution to journalArticle

Jann, Michael W. ; Spratlin, Vicky ; Momary, Kathryn ; Zhang, Hailing ; Turner, David ; Penzak, Scott R. ; Wright, Alan ; VanDenBerg, Chad. / Lack of a pharmacokinetic drug-drug interaction with venlafaxine extended-release/indinavir and desvenlafaxine extended-release/indinavir. In: European Journal of Clinical Pharmacology. 2012 ; Vol. 68, No. 5. pp. 715-721.
@article{16ab3fe5e03442ea9a42d63927feb204,
title = "Lack of a pharmacokinetic drug-drug interaction with venlafaxine extended-release/indinavir and desvenlafaxine extended-release/indinavir",
abstract = "Purpose: To assess the effects of venlafaxine extended-release (XR) capsules and desvenlafaxine extended-release (XR) tablets upon indinavir pharmacokinetic properties when co-administrated to healthy volunteers. Methods: This was an open-label, two-period, fixed-dose study conducted at the clinical research unit located on a university campus. Twenty-four healthy volunteers enrolled in the study (mean age 28.3±8.0 years). Each subject received a single dose of indinavir 800 mg on day 1. Subsequently, subjects were then randomly assigned to either the venlafaxine XR group (N012) or the desvenlafaxine XR group (N012). Starting on day 2, venlafaxine XR was dosed at 37.5 mg/day for 4 days and increased to 75 mg/day for 6 days. Desvenlafaxine XR was dosed at 50 mg/day for 10 days. On day 12, indivanvir 800 mg was co-administered to both the venlafaxine XR and the desvenlafaxine XR groups. The pharmacokinetics of indinavir were determined both before and at the end of antidepressant dosing. Plasma indinavir, venlafaxine, and desvenlafaxine concentrations were assayed by highperformance liquid chromatography with ultra-violet (UV) detection. Indinavir pharmacokinetic parameters were calculated by noncompartmental analysis using validated computer software. Results: Venlafaxine XR and desvenlafaxine XR did not produce any significant changes in indinavir disposition. Both antidepressants were well tolerated by the subjects with only minor adverse side effects. Conclusions: No pharmacokinetic drug-drug interaction was demonstrated between venlafaxine XR and indinavir or between desvenlafaxine XR and indinvair. The lack of interaction could be due to the venlafaxine and desvenlafaxine extended-release formulation.",
keywords = "Desvenlafaxine XR, Drug interaction, Indinavir, P-glycoprotein, Venlafaxine XR",
author = "Jann, {Michael W.} and Vicky Spratlin and Kathryn Momary and Hailing Zhang and David Turner and Penzak, {Scott R.} and Alan Wright and Chad VanDenBerg",
year = "2012",
month = "5",
day = "1",
doi = "10.1007/s00228-011-1180-7",
language = "English (US)",
volume = "68",
pages = "715--721",
journal = "European Journal of Clinical Pharmacology",
issn = "0031-6970",
publisher = "Springer Verlag",
number = "5",

}

TY - JOUR

T1 - Lack of a pharmacokinetic drug-drug interaction with venlafaxine extended-release/indinavir and desvenlafaxine extended-release/indinavir

AU - Jann, Michael W.

AU - Spratlin, Vicky

AU - Momary, Kathryn

AU - Zhang, Hailing

AU - Turner, David

AU - Penzak, Scott R.

AU - Wright, Alan

AU - VanDenBerg, Chad

PY - 2012/5/1

Y1 - 2012/5/1

N2 - Purpose: To assess the effects of venlafaxine extended-release (XR) capsules and desvenlafaxine extended-release (XR) tablets upon indinavir pharmacokinetic properties when co-administrated to healthy volunteers. Methods: This was an open-label, two-period, fixed-dose study conducted at the clinical research unit located on a university campus. Twenty-four healthy volunteers enrolled in the study (mean age 28.3±8.0 years). Each subject received a single dose of indinavir 800 mg on day 1. Subsequently, subjects were then randomly assigned to either the venlafaxine XR group (N012) or the desvenlafaxine XR group (N012). Starting on day 2, venlafaxine XR was dosed at 37.5 mg/day for 4 days and increased to 75 mg/day for 6 days. Desvenlafaxine XR was dosed at 50 mg/day for 10 days. On day 12, indivanvir 800 mg was co-administered to both the venlafaxine XR and the desvenlafaxine XR groups. The pharmacokinetics of indinavir were determined both before and at the end of antidepressant dosing. Plasma indinavir, venlafaxine, and desvenlafaxine concentrations were assayed by highperformance liquid chromatography with ultra-violet (UV) detection. Indinavir pharmacokinetic parameters were calculated by noncompartmental analysis using validated computer software. Results: Venlafaxine XR and desvenlafaxine XR did not produce any significant changes in indinavir disposition. Both antidepressants were well tolerated by the subjects with only minor adverse side effects. Conclusions: No pharmacokinetic drug-drug interaction was demonstrated between venlafaxine XR and indinavir or between desvenlafaxine XR and indinvair. The lack of interaction could be due to the venlafaxine and desvenlafaxine extended-release formulation.

AB - Purpose: To assess the effects of venlafaxine extended-release (XR) capsules and desvenlafaxine extended-release (XR) tablets upon indinavir pharmacokinetic properties when co-administrated to healthy volunteers. Methods: This was an open-label, two-period, fixed-dose study conducted at the clinical research unit located on a university campus. Twenty-four healthy volunteers enrolled in the study (mean age 28.3±8.0 years). Each subject received a single dose of indinavir 800 mg on day 1. Subsequently, subjects were then randomly assigned to either the venlafaxine XR group (N012) or the desvenlafaxine XR group (N012). Starting on day 2, venlafaxine XR was dosed at 37.5 mg/day for 4 days and increased to 75 mg/day for 6 days. Desvenlafaxine XR was dosed at 50 mg/day for 10 days. On day 12, indivanvir 800 mg was co-administered to both the venlafaxine XR and the desvenlafaxine XR groups. The pharmacokinetics of indinavir were determined both before and at the end of antidepressant dosing. Plasma indinavir, venlafaxine, and desvenlafaxine concentrations were assayed by highperformance liquid chromatography with ultra-violet (UV) detection. Indinavir pharmacokinetic parameters were calculated by noncompartmental analysis using validated computer software. Results: Venlafaxine XR and desvenlafaxine XR did not produce any significant changes in indinavir disposition. Both antidepressants were well tolerated by the subjects with only minor adverse side effects. Conclusions: No pharmacokinetic drug-drug interaction was demonstrated between venlafaxine XR and indinavir or between desvenlafaxine XR and indinvair. The lack of interaction could be due to the venlafaxine and desvenlafaxine extended-release formulation.

KW - Desvenlafaxine XR

KW - Drug interaction

KW - Indinavir

KW - P-glycoprotein

KW - Venlafaxine XR

UR - http://www.scopus.com/inward/record.url?scp=84864286853&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864286853&partnerID=8YFLogxK

U2 - 10.1007/s00228-011-1180-7

DO - 10.1007/s00228-011-1180-7

M3 - Article

C2 - 22173281

AN - SCOPUS:84864286853

VL - 68

SP - 715

EP - 721

JO - European Journal of Clinical Pharmacology

JF - European Journal of Clinical Pharmacology

SN - 0031-6970

IS - 5

ER -